Preclinical Evaluation of the Multiple Tyrosine Kinases Inhibitor Anlotinib in Leukemia Stem Cells

• Main Authors: Yuelong Jiang (Author), Long Liu (Author), Yirong Jiang (Author), Zhifeng Li (Author), Liying Feng (Author), Xinguo Zhuang (Author), Zhijuan Lin (Author), Qiuling Chen (Author), Guoshu Chen (Author), Jixiang He (Author), Guowei Li (Author), Jie Zha (Author), Bing Xu (Author)
• Format: Book
• Published: MDPI AG, 2022-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Leukemia stem cells (LSCs) constitute the critical barrier to the cure of acute myeloid leukemia (AML) due to their chemoresistance and immune evasion property. Herein, the role of anlotinib, a multiple tyrosine kinase inhibitor, in killing LSCs and regulating chemoresistance and immune evasion was...